PGx testing detects specific genetic variations in genes that encode enzymes responsible for the breakdown (metabolism) of many medications. This information may tell us how an individual will respond to a particular medication. In some cases, a medication is contraindicated (which means it should be avoided) based on PGx results and an alternative medication should be considered. In some cases, the dosage should be modified.

PGx testing provides information about specific gene and drug interactions and whether alternate dosage or medications should be considered. This may be important to evaluate prior to beginning a new medication, adjusting dosage, or planning future medications. However, test results do not determine which specific medication would be indicated. While there are “normal” variants, the combination of different genetic variants in a person may impact their unique response to medications. Clinical judgement should be used to determine other genetic and non-genetic factors that may impact medication response.

Lineagen’s PGx test is designed for patients being treated with one or more drugs to address the symptoms of  neurodevelopmental disorders, such as epileptic seizures, anxiety, and/or attention deficit, and focuses on drug-gene interaction information with a substantial level of literature-based scientific evidence. The levels of evidence can be found at the Clinical Pharmacogenetics Implementation Consortium and PharmGKB.

PGx testing looks at genetic changes called single nucleotide polymorphisms (SNPs) within specific genes known to be related to “drug metabolism.” CMA looks at all areas within the genome for deletions or duplications, called copy number variations (CNVs), to pinpoint a “genetic diagnosis” for an individual’s neurodevelopmental clinical features.

Yes, PGx testing can be performed using the same buccal sample that is collected for FirstStep^Dx PLUS. Learn how to order here.

We estimate the turnaround time to be about 3 to 4 weeks.